Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vemurafenib + cytarabine + cladribine
- Development stage
- Phase 2
- Lead developer
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
vemurafenib + cytarabine + cladribine is a combination therapy regimen being investigated by the Federal Research Institute of Pediatric Hematology, Oncology and Immunology for the treatment of Langerhans cell histiocytosis (LCH). The regimen combines the BRAF inhibitor vemurafenib with two antimetabolite chemotherapeutic agents, cytarabine and cladribine (also known as 2-chlorodeoxyadenosine). This combination is specifically targeted at pediatric patients with multisystem LCH harboring the BRAF V600E mutation. The rationale for this triple therapy is to combine the rapid clinical response provided by targeted BRAF inhibition with the cytotoxic effects of low-dose chemotherapy to achieve a durable complete response and prevent the disease reactivation often observed upon discontinuation of BRAF inhibitor monotherapy.
- Other names
- 2-chlorodeoxyadenosine + cytarabine + vemurafenibcladribine + cytarabine + vemurafenibVemurafenib with Cytarabine and Cladribine
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)DNADNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on vemurafenib + cytarabine + cladribine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vemurafenib + cytarabine + cladribine.